Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP Into a Paradigm of Integrated Care.

Competing Interests: Funding Support and Author Disclosures Dr Lala is a member of the Speakers Bureau for Abiomed and Zoll; participates in contracted research for Merck, Bayer, and AstraZeneca; and serves on advisory boards for Novo Nordisk and Boehringer Ingelheim. Dr Ostrominski has reported that he has no relationships relevant to the contents of this paper to disclose.